ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (“Ambry”) announces the launch of powerful cardiovascular genetic testing panels for inherited cardiomyopathies and arrhythmias. These feature an intuitive, tiered approach to testing for hypertrophic cardiomyopathy, long QT syndrome, and Brugada syndrome. Sudden death may be the first and only symptom of some of these disorders. Genetic testing can be life-saving and directly impacts medical care when confirming a diagnosis and/or identifying at-risk individuals. These new panels feature Ambry’s superior next generation sequencing, deletion/duplication analysis, comprehensive coverage, and turnaround times as low as 3-4 weeks.
Help employers find you! Check out all the jobs and post your resume.
